DGAP-News

MOLOGEN AG: Positive subgroup results of the exploratory phase II IMPULSE study of lefitolimod in extensive-disease small-cell lung cancer (SCLC)

DGAP-News: MOLOGEN AG / Key word(s): Study results MOLOGEN AG: Positive subgroup results of the exploratory phase II IMPULSE study of lefitolimod in extensive-disease small-cell lung cancer (SCLC) 24.04.2017 / 07:26 The issuer is solely responsible for the content of this announcement. Press Release N 9 / 2017 on 24 April 2017

MOLOGEN AG: Positive subgroup results of the exploratory phase II IMPULSE study of lefitolimod in extensive-disease small-cell lung cancer (SCLC)

- Clinically relevant subgroups benefit from the treatment with lefitolimod in this study

- Results are indicative for the further development of lefitolimod in SCLC

Berlin, 24 April 2017 - The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced the key results of the exploratory phase II IMPULSE study. The randomized study evaluated the efficacy and safety of lefitolimod in patients with extensive-disease small-cell lung cancer (SCLC). IMPULSE shows positive results regarding overall survival (OS) in two subgroups of patients in comparison to the control group (standard therapy). Additional, potentially promising subgroups will be identified. The results of this SCLC study provide significant guidance for defining patient populations that, even beyond this study, are most likely to benefit from the immune surveillance reactivator lefitolimod, even though in this highly challenging indication the primary endpoint OS was not met in the overall study population.


"Lung cancer, and especially small-cell lung cancer, is an indication for which the benefit of current standard treatment is very limited. We are therefore very pleased to see initial evidence of clinical efficacy for lefitolimod in small-cell lung cancer, an indication known for its setbacks in other drug development programs," said Dr Mariola Soehngen, CEO of MOLOGEN AG. "The data of the IMPULSE study, especially from the two identified subgroups, show that lefitolimod has the potential to become an important treatment option - also for patients with a disease as difficult to treat as small-cell lung cancer. Notably, these positive study results will be an important asset in the ongoing partnering discussions."